This trial is comparing two treatments for cervical cancer. The first treatment is cemiplimab and the second is chemotherapy. The goal is to see which treatment is better at overall survival, progression-free survival, objective response rate, duration of response, and quality of life.
2 Primary · 11 Secondary · Reporting Duration: Time from randomization up to approximately 44 months
608 Total Participants · 2 Treatment Groups
Primary Treatment: Cemiplimab · No Placebo Group · Phase 3
Age 18+ · Female Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: